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TSH-induced cyclic AMP accumulation in dog thyroid slices is inhibited by norepinephrine through an CQ- 
adrenergic receptor, by carbamylcholine through a muscarinic cholinergic receptor, and by iodide. The 
inhibitory effect of iodide bears on the adenylate cyclase, but the exact mechanism of its action is still un- 
known. It is known that norepinephrine acts through activation of the N, subunit of the cyclase, and that 
carbamylcholine, activating a phosphodiesterase, acts independently of N,. IAP (islet-activating protein) has 
been shown to inactivate the N,subunit. We studied the effect of IAP on the inhibitory action of iodide, 
norepinephrine, and carbamylcholine oncyclic AMP accumulation i  TSH-stimulated thyroid slices. In- 
cubations of I5 or 22 h, and relatively high concentrations of IAP (250 ng/ml) were necessary to demonstrate 
an effect of IAP on thyroid slices. We report here that, under those conditions, inhibition of cyclic AMP 
accumulation by norepinephrine, but not by carbamylcholine or iodide, was suppressed by IAP treatment. 
These results indicate that the cyclase inhibition by iodide, is either not mediated by N,, or if mediated by 
N,, involves a mode of regulation of this coupling protein that is different from that by which the other 
‘N,-mediated’ inhibitory hormones act on the enzyme. 
IAP Thyroid Cyclic AMP Norepinephrine Iodide 
1. INTRODUCTION 
Thyroid intracellular cyclic AMP concentration 
in dog stimulated tissue, is negatively regulated by 
agents acting at the level of its synthesis 
(norepinephrine, iodide), or its degradation (car- 
bamylcholine). As previously shown [1,2], 
norepinephrine inhibits the thyroid adenylate 
cyclase through activation of an uz-adrenergic 
receptor. By analogy with other systems [3,4], it 
has been suggested that norepinephrine inhibits 
thyroid adenylate cyclase by activating Ni, the 
guanine nucleotide regulatory subunit of the 
adenylate cyclase complex, which is involved in 
hormone-induced inhibition of the enzyme [5-91. 
Abbreviations: Ni, inhibitory nucleotide binding 
regulatory component of adenylate cyclase; TSH, 
thyroid-stimulating hormone; IAP, islet-activating 
protein 
On the contrary, it has been shown that, in the 
same system, carbamylcholine does not act at the 
level of the cyclase, but induces a decrease in cyclic 
AMP concentration by activating a Ca2+-calmod- 
ulin-sensitive phosphodiesterase [lo], i.e., in a 
Ni-independent manner. Finally, iodide, in an 
organified form, inhibits thyroid adenylate cyclase 
through a mechanism that is still unknown [l 11. 
Islet-activating protein (IAP), a toxin isolated 
from the culture medium of Bordetella pertussis, 
activates the adenylate cyclase system of a variety 
of cell types [12,13]. IAP catalyzes the ADP- 
ribosylation of a membranous protein which has 
been identified as the Ni subunit, and thereby 
blocks the receptor-mediated inhibition of cyclase 
[ 14,151. IAP impairs or abolishes the inhibitory ef- 
fect of a-adrenergic agonists, dopamine agonists, 
cholinergic muscarinic or opiate agonists, in 
platelet membranes, pituitary cells, and 
neuroblastoma x glioma hybrid cells respectively 
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[ 16-181. It is thus a useful probe to demonstrate 
the role of Ni in the action of inhibitory agents on 
adenylate cyclase. Here, IAP was therefore used 
for further investigation of the inhibition of 
thyroid cyclic AMP system by norepinephrine, car- 
bamylcholine, and iodide. 
2. MATERIALS AND METHODS 
We are very grateful to Dr K.H. Jakobs and Dr 
G. Schultz for giving us some IAP. TSH was from 
Armour Pharmaceuticals, Ro 20-1724 from 
Roche, iodide from Merck, carbamylcholine from 
ICN Pharmaceuticals, norepinephrine from 
Sigma, and 1-propranolol from ICI. 
Thyroids from freshly killed animals were sliced 
at room temperature, and incubated at 37°C under 
an atmosphere of 02 : CO2 (95 : 5, v/v), in Krebs- 
Ringer bicarbonate buffer enriched with 8 mM 
glucose, 0.5 g/l bovine serum albumin, 100 U/ml 
penicillin, and 100 rg/ml streptomycin. About 
40 mg of slices were incubated in 2 ml of medium. 
IAP was added at the beginning of the incubation, 
which lasted several hours before addition of 
iodide, norepinephrine, carbamylcholine, and 
TSH. Ro 20-1724 (a phosphodiesterase inhibitor), 
and I-propranolol (a P-antagonist, added in order 
to block the P-effect of norepinephrine), were add- 
ed simultaneously with TSH. The incubation was 
ended by dropping the slices into boiling water for 
5 min. The slices were then homogenized, cen- 
trifuged, and lyophilized. The tissue extract was 
resuspended in water, and the cyclic AMP concen- 
tration was determined by the method of Gilman, 
as previously described [ 191. 
3. RESULTS AND DISCUSSION 
Table 1 shows that cyclic AMP accumulation in 
TSH-stimulated dog thyroid slices incubated dur- 
ing 6% h with IAP, was inhibited by 
norepinephrine as in control slices. This inhibition 
was completely suppressed when the incubation 
with IAP lasted 15 or 22 h. This is consistent with 
the results obtained by other groups, showing that 
several hours are necessary to establish IAP effect 
[20,21]. It must be noted that, after a 24-h incuba- 
tion, thyroid slices still respond normally to 
positive and negative control of adenylate cyclase, 
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Table 1 
Time dependency of reversal of norepinephrine 
inhibitory effect by IAP 
Incubation time 
6% h 15 h 22 h 
TSH 1155 k 72 1794 + 217 1381 + 142 
TSH + nor- 
epinephrine 
070 inhibition 
683 + 30 1042 + 23 836 + 69 
41 42 39 
TSH + IAP 1439 * 238 2435 f 14 1900 k 624 
TSH + IAP + 
norepi- 
nephrine 740 5 81 2423 + 229 2211 + 235 
% inhibition 49 0 0 
IAP was added from the onset of the incubation; 
norepinephrine, TSH, Ro 20-1724, and I-propranolol 
were always added 1 h before the end of the incubation. 
Norepinephrine, Ro 20-1724, and I-propranolol were 
10m4 M. TSH was 0.5 mU/mI and IAP 2.5 pg/ml in the 
6% h incubation. TSH was 1 mu/ml and IAP 
250 ng/ml in the 15 and 22 h incubations. Results are 
expressed as pmoles cyclic AMP/100 mg wet wt tissue, 
means of triplicates + SE 
which demonstrates, as shown earlier for other 
parameters [22], a good survival. 
The reversal by IAP of norepinephrine-induced 
inhibition of adenylate cyclase activity in dog 
thyroid slices was concentration-dependent. 
Thyroid slices were incubated 15 h with IAP. TSH 
1 mu/ml, 10m4 M norepinephrine, 1O-4 M 
Ro 20-1724, and 10e4 M I-propranolol were added 
1 h before the end of the incubation. The inhibi- 
tion of TSH-induced cyclic AMP accumulation by 
norepinephrine obtained in the absence of IAP was 
about 50%. The concentrations of IAP tested were 
10,25, 100, and 250 ng/ml. IAP was only effective 
at 25 ng/ml, and relieved half of the inhibition at 
100 ng/ml. At 250 ng/ml IAP, the norepinephrine 
inhibition was suppressed. 
We studied the effect of IAP treatment on the 
action of three well known inhibitors of cyclic 
AMP accumulation in TSH-stimulated thyroid 
slices: norepinephrine, carbamylcholine, and 
iodide [2,10,11]. Data presented in table 2, show 
that only the norepinephrine inhibitory effect was 
impaired by IAP treatment. As expected, car- 
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Table 2 
Effect of IAP on norepinephrine, carbamylcholine and iodide inhibitory action 
Experiment 070 Experiment 070 Experiment % 
no. 1 inh. no.2 inh. no.3 inh. 
TSH 1679 f 167 1381 -+ 142 1637 f 25 
TSH + norepinephrine 885 k 61 47 836 f 69 39 820 + 114 50 
TSH + iodide 1068 + 207 36 906 f 91 34 1337 + 136 18 
TSH + norepinephrine + iodide 877 + 28 46 
TSH + carbamylcholine 1021 + 16 38 
TSH + IAP 2124 k 432 1900 + 624 2552 + 473 
TSH + IAP + norepinephrine 2103 + 174 0 2211+235 0 2327 + 401 9 
TSH + IAP + iodide 1306 + 19 39 971 * 211 49 2193 1?1 482 14 
TSH + IAP + norepinephrine + iodide 1955 k 138 23 
TSH + IAP + carbamylcholine 1302 + 258 49 
Dog thyroid slices were incubated 22 h, with or without IAP (250 ng/ml). Iodide, low4 M, was added 14 h after the 
onset of the incubation. Norepinephrine, I-propranolol, and Ro 20-1724, each 10e4 M, carbamylcholine, lo-’ M, and 
TSH, 1 mu/ml, were added 1 h before the end of the incubation. Results are expressed as pmol cyclic AMP/100 mg 
wet wt tissue + SE 
bamylcholine inhibitory effect, that has been 
shown to be mediated through an activation by 
Ca2+ of a calmodulin-sensitive phosphodiesterase 
[lo], was not relieved by IAP. The iodide in- 
hibitory effect, although bearing on the cyclase 
[ 111, was not relieved by IAP treatment. 
One explanation for this result is that iodide 
could interfere with IAP in such a manner that 
IAP is no more effective in inactivating Ni. To test 
this hypothesis, norepinephrine and iodide were 
both added to IAP-treated and control slices, to 
see whether or not the presence of iodide prevented 
the suppression by IAP of norepinephrine in- 
hibitory effect. When norepinephrine and iodide 
were added to the same TSH-stimulated slices, 
their inhibitory effects were not additive (table 2). 
IAP relieved the inhibition of iodide and 
norepinephrine to the level reached with iodide 
alone. Moreover, iodide did not interfere with the 
enhancement of TSH action by IAP. These results 
indicate that IAP impairs norepinephrine but not 
iodide effect, and also, that iodide does not hinder 
IAP effect on norepinephrine inhibitory action. 
We have investigated whether or not the absence 
of effect of IAP on the iodide inhibitory action 
was specific to the dog thyroid. Using the same ex- 
perimental conditions, the iodide inhibitory effect 
on horse thyroid adenylate cyclase was not sup- 
pressed in IAP-treated horse thyroid slices (not 
shown). 
In conclusion, IAP, a known inhibitor of the 
negative subunit Ni of the adenylate cyclase com- 
plex [ 14,151, relieves &2-adrenergic inhibitory ac- 
tion on dog thyroid adenylate cyclase, but does not 
impair carbamylcholine inhibitory effect on cyclic 
AMP accumulation. Thus, the use of IAP allowed 
us to confirm the results previously obtained in this 
system [2,10,11], i.e., norepinephrine, but not car- 
bamylcholine, acts through Ni. As the inhibitory 
effect of iodide was not relieved by IAP, IAP per- 
mitted discrimination between two agents, both in- 
hibiting the synthesis of cyclic AMP : norepineph- 
rine, and iodide. The data presented suggest hat 
the inhibition by iodide is not mediated by Ni, or 
if mediated by Ni, involves a mode of regulation of 
this coupling protein that is different from that by 
which the other Ni-mediated inhibitory hormones 
act on the cyclase. Another example of direct 
negative regulation on cyclase which may not in- 
volve Ni is the recently reported action of pro- 
gesterone on oocytes [23]. 
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